The burgeoning landscape of treatment for obesity and type 2 diabetes is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant variations in their pharmacological profiles and clinical trial results are emerging. Retatrutide, boasting a s

Arriving in the landscape of weight management treatment, retatrutide represents a distinct method. Beyond many available medications, retatrutide functions as a dual agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. This dual stimulation encourages multiple adv